Henry Schein, Inc. HSIC
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +14.61%
- 1 year
- +37.06%
- Open
- 85.93
- Prev close
- 84.88
- Mkt cap
- 9.65B
- Vol
- 2.50M
- Avg vol
- 1.16M
- EPS
- 3.50
- P/E
- 24.75
- Div yield
- 0.00%
More statistics
- Low
- 85.38
- High
- 87.28
- Forward P/E
- 14.46
- Beta
- 0.86
- Short ratio
- 6.93
- Inst. own
- 111.14%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 86.53
- 200-d avg
- 81.06
- 1y target
- 96.87
5D chart
Signals (114)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:50 PM | 10 hours ago |
| SMA: Bullish | Nov 2, 3:45 PM | 10 hours ago |
| SMA: Bearish | Nov 2, 3:40 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 3:35 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 3:15 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 3:10 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 2:30 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 2:20 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 2:15 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 1:45 PM | 12 hours ago |
| MACD: Sell Signal | Nov 2, 1:45 PM | 12 hours ago |
| MACD: Buy Signal | Nov 2, 1:25 PM | 13 hours ago |
| SMA: Bullish | Nov 2, 1:00 PM | 13 hours ago |
| SMA: Bearish | Nov 2, 12:10 PM | 14 hours ago |
| MACD: Sell Signal | Nov 2, 12:05 PM | 14 hours ago |
| RSI: Overbought | Nov 2, 11:35 AM | 15 hours ago |
| RSI: Overbought | Nov 2, 11:25 AM | 15 hours ago |
| MACD: Buy Signal | Nov 2, 10:50 AM | 15 hours ago |
| SMA: Bullish | Nov 2, 10:45 AM | 15 hours ago |
| MACD: Sell Signal | Nov 2, 10:30 AM | 16 hours ago |
Newest 20 of 114.
News
3 days ago zacks.com
Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
6 days ago zacks.com
Analysts Estimate Henry Schein (HSIC) to Report a Decline in Earnings: What to Look Out for
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 days ago zacks.com
Henry Schein to Report Q3 Earnings: Here's What You Should Know
HSIC gears up for Q3 earnings with revenue growth expected across its three segments, fueled by dental products, specialty demand and cloud-based technology.
1 week ago businesswire.com
Henry Schein to Webcast Third Quarter 2026 Conference Call on Tuesday, November 3, 2026, at 8:00 a.m. ET
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will…
2 weeks ago zacks.com
Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
-
2 weeks ago benzinga.com
Leerink Partners Maintains Market Perform on Henry Schein, Lowers Price Target to $92
Leerink Partners analyst Michael Cherny maintains Henry Schein (NASDAQ:HSIC) with a Market Perform and lowers the price target from $96 to $92.
2 weeks ago zacks.com
Henry Schein (HSIC) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 weeks ago businesswire.com
Henry Schein Announces Chief Financial Officer Leadership Transition
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced today that Emmanuel Caprais, former Senior Vice President and Chief Financial Officer of ITT, Inc. (NYSE: ITT), has been…
3 weeks ago zacks.com
HSIC or MMSI: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Henry Schein (HSIC) or Merit Medical (MMSI). But which of these two stocks presents investors with…
3 weeks ago zacks.com
Should Value Investors Buy Henry Schein (HSIC) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
1 month ago businesswire.com
Henry Schein Cares Marks 25 Years of Helping Health Happen®
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Cares, Henry Schein, Inc.'s global corporate citizenship program, is celebrating a quarter century of bringing together Team Schein Members, customers,…
1 month ago benzinga.com
Transcript: Henry Schein Q2 2026 Earnings Conference Call
Henry Schein (NASDAQ:HSIC) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive…
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Vistagen Therapeutics (NASDAQ:VTGN) shares…
1 month ago zacks.com
Here's Why Henry Schein (HSIC) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
1 month ago seekingalpha.com
Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher
Henry Schein remains a dominant global provider of dental and medical practitioner supplies, with recent share price outperformance versus the S&P 500. HSIC delivered strong Q2 results: revenue up…
1 month ago zacks.com
Are Investors Undervaluing Henry Schein (HSIC) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
1 month ago zacks.com
What Makes Henry Schein (HSIC) a New Buy Stock
Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
1 month ago zacks.com
HSIC or SAUHY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Dental Supplies stocks are likely familiar with Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks offers value investors a better…
1 month ago zacks.com
Here's Why Henry Schein (HSIC) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
1 month ago seekingalpha.com
Henry Schein: Growth Is Improving, But The Valuation Stays Cheap
Henry Schein is rated buy with a 12-month price target of $104, reflecting accelerating organic growth, margin expansion, and substantial share repurchases. Q2 2026 results showed 4.6% internal…
1 month ago seekingalpha.com
Henry Schein, Inc. (HSIC) Presents at 2026 Global Healthcare Conference Transcript
Henry Schein, Inc. (HSIC) Presents at 2026 Global Healthcare Conference Transcript
1 month ago businesswire.com
Applied BioCode Announces Distribution Agreement with Henry Schein
SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)-- #ClinicalDiagnostics--Applied BioCode today announced a distribution agreement with Henry Schein, a leading provider of healthcare products and services,…
1 month ago businesswire.com
Henry Schein to Participate in Upcoming Investor Conference in September
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Company will…
2 months ago benzinga.com
Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts changed outlook on top names. Piper Sandler raises Mercury Systems' target price, Ascendiant Capital boosts Alzamend Neuro's target price, BTIG raises Henry Schein's target price, Cantor…
-
2 months ago benzinga.com
BTIG Maintains Buy on Henry Schein, Raises Price Target to $110
BTIG analyst David Larsen maintains Henry Schein (NASDAQ:HSIC) with a Buy and raises the price target from $100 to $110.
-
2 months ago benzinga.com
Barclays Maintains Overweight on Henry Schein, Raises Price Target to $100
Barclays analyst Glen Santangelo maintains Henry Schein (NASDAQ:HSIC) with a Overweight and raises the price target from $86 to $100.
-
2 months ago benzinga.com
UBS Maintains Neutral on Henry Schein, Raises Price Target to $94
UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the price target from $89 to $94.
-
2 months ago benzinga.com
Citigroup Maintains Buy on Henry Schein, Raises Price Target to $112
Citigroup analyst Daniel Grosslight maintains Henry Schein (NASDAQ:HSIC) with a Buy and raises the price target from $100 to $112.
-
3 months ago benzinga.com
Henry Schein Q2 2026 Earnings Call: Complete Transcript
Henry Schein (NASDAQ:HSIC) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to…
-
3 months ago benzinga.com
Henry Schein Raises FY2026 Adj EPS Guidance from $5.23-$5.37 to $5.29-$5.39 vs $5.33 Est; Raises FY2026 Sales Guidance from $13.580B-$13.843B to $13.794B-$13.926B vs $13.738B Est
Henry Schein (NASDAQ:HSIC) raises FY2026 Adj EPS guidance from $5.23-$5.37 to $5.29-$5.39 vs $5.33 analyst estimate. Raises FY2026 sales outlook from $13.580 billion-$13.843 billion to $13.794…
-
3 months ago benzinga.com
Henry Schein Q2 Adj. EPS $1.27 Beats $1.24 Estimate, Sales $3.458B Beat $3.375B Estimate
Henry Schein (NASDAQ:HSIC) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.24 by 2.42 percent. This is a 15.45 percent increase over earnings of $1.10…
-
3 months ago benzinga.com
Piper Sandler Maintains Overweight on Henry Schein, Raises Price Target to $95
Piper Sandler analyst Jason Bednar maintains Henry Schein (NASDAQ:HSIC) with a Overweight and raises the price target from $91 to $95.
-
3 months ago benzinga.com
UBS Maintains Neutral on Henry Schein, Raises Price Target to $89
UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the price target from $85 to $89.
-
3 months ago benzinga.com
BMO Capital Initiates Coverage On Henry Schein with Market Perform Rating, Announces Price Target of $85
BMO Capital initiates coverage on Henry Schein (NASDAQ:HSIC) with a Market Perform rating and announces Price Target of $85.
4 months ago benzinga.com
This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Wall Street analysts changed outlook on top names like MKTX, PRCT, VOD, and JILL. See ratings page and analysts' views before buying MKTX stock.
4 months ago benzinga.com
This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Wall Street analysts change outlook for top stocks. See upgrades, downgrades, and initiations on analyst ratings page. HSIC stock analysis.
-
4 months ago benzinga.com
BTIG Upgrades Henry Schein to Buy, Announces $100 Price Target
BTIG analyst David Larsen upgrades Henry Schein (NASDAQ:HSIC) from Neutral to Buy and announces $100 price target.
-
5 months ago benzinga.com
Henry Schein Appoints William K. Daniel As Board Chairman, Effective Immediately
Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected…
-
6 months ago benzinga.com
UBS Maintains Neutral on Henry Schein, Lowers Price Target to $85
UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and lowers the price target from $87 to $85.
-
6 months ago benzinga.com
Mizuho Maintains Neutral on Henry Schein, Lowers Price Target to $82
Mizuho analyst Steven Valiquette maintains Henry Schein (NASDAQ:HSIC) with a Neutral and lowers the price target from $88 to $82.
6 months ago benzinga.com
Transcript: Henry Schein Q1 2026 Earnings Conference Call
Transcript: Henry Schein Q1 2026 Earnings Conference Call
-
6 months ago benzinga.com
Henry Schein Affirms FY2026 Adj EPS Guidance of $5.23-$5.37 vs $5.32 Est; Affirms FY2026 Sales Guidance of $13.580B-$13.843B vs $13.717B Est
Henry Schein (NASDAQ:HSIC) affirms FY2026 Adj EPS guidance from $5.23-$5.37 to $5.23-$5.37 vs $5.32 analyst estimate. Affirms FY2026 sales outlook from $13.580 billion-$13.843 billion to $13.580…
-
6 months ago benzinga.com
Henry Schein Q1 Adj. EPS $1.32 Beats $1.22 Estimate, Sales $3.368B Beat $3.342B Estimate
Henry Schein (NASDAQ:HSIC) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.22 by 8.2 percent. This is a 14.78 percent increase over earnings of $1.15…
-
6 months ago benzinga.com
Morgan Stanley Maintains Underweight on Henry Schein, Raises Price Target to $64
Morgan Stanley analyst Erin Wright maintains Henry Schein (NASDAQ:HSIC) with a Underweight and raises the price target from $61 to $64.
6 months ago benzinga.com
This Dick's Sporting Goods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top analysts change outlook on top names, check analyst ratings page for all changes. Keybanc initiated Overweight rating on KALU with $170 PT.
-
6 months ago benzinga.com
Citigroup Initiates Coverage On Henry Schein with Buy Rating, Announces Price Target of $100
Citigroup analyst Daniel Grosslight initiates coverage on Henry Schein (NASDAQ:HSIC) with a Buy rating and announces Price Target of $100.
-
6 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Henry Schein, Lowers Price Target to $90
Evercore ISI Group analyst Elizabeth Anderson maintains Henry Schein (NASDAQ:HSIC) with a Outperform and lowers the price target from $100 to $90.
-
6 months ago benzinga.com
Henry Schein Chairman Stanley M. Bergman to Retire After 44 Years, Board Shrinks to 10 Members
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, today announced its plan to reduce the size of its Board of…
-
8 months ago benzinga.com
Biomerica Announces Responder Analysis Results From Ongoing Real-World Study Of inFoods IBS
Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's…